Clinical and Serological Predictors of Remission in Rheumatoid Arthritis Are Dependent on Treatment Regimen

Margaret, H.; Scott, Ian C.; Dahanayake, Chanaka; Cope, Andrew P.; Scott, David

doi:10.3899/jrheum.131401

Cited by 13 publications

(10 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because the original aim of the CARDERA studies was to investigate the performance of combination therapy with reference to monotherapy, a placebo group was not assigned. Rheumatoid factor (RF), a biomarker providing clinical information on the antibody composition of patient serum, was assayed as described previously (16). Follow-up was 2 years.…”

Section: Methodsmentioning

confidence: 99%

The Relationship Between Mental Health, Disease Severity, and Genetic Risk for Depression in Early Rheumatoid Arthritis

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

The Relationship Between Mental Health, Disease Severity, and Genetic Risk for Depression in Early Rheumatoid Arthritis

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…In case of refractory subjects, Disease Modifying Antirheumatic Drugs (DMARDs) and Anti-Tumor Necrosis Factor-α (anti-TNF-α) drugs are effective. 3 Dermatomyositis: It is an inflammatory myopathy which can affect children or adults. The clinical features inlcude progressive proximal muscle weakness and skin rash.…”

Section: Description Of Different Types Of Arthritis Patientsmentioning

confidence: 99%

“…Around 10% of the patients had very high titre values (Table 1). 3 C-reactive protein is an acute phase reactant that is widely used and a rise in its concentration is correlated with disease activity. CRP is a better marker than ESR which could identify the inflammatory burden and it closely overlaps with TJC, SJC and pain scale (VAS).…”

Section: Biochemical and Serological Profiles Of Ra Patientsmentioning

confidence: 99%

Epidemiology of Autoimmune Disorders with Special Reference to Rheumatoid Arthritis from a Tertiary Care Center

Premkumar¹,

M²,

Rajagopa³

et al. 2014

IJOPP

View full text Add to dashboard Cite

Background: Autoimmune disorders (AID) are emerging non-communicable diseases and understanding their epidemiology could reveal information about their clinical characteristics and disease management. Objective: To record the different types of arthritis cases attending a tertiary care center and study the profile of rheumatoid arthritis cases. Methods: The different types of arthritis cases reported were recorded from both rheumatologic and orthopaedic units. Retrospectively data was collected from Medical records department. Results and discussion: Totally 1481 cases were taken for the study. The proportion of females getting affected with AID were high and the ratio of female: male was found to be 2.25:1. There were around 30 types of different arthritis cases which are reported. The different types of arthritis were rheumatoid arthritis (RA) (39%), fibromyalgia (13%), spondyloarthropathy (9%), systemic lupus erythematosus (6%), psoriatic arthritis (6%), Sjogren's syndrome (5%), reactive arthritis (5%), osteoarthritis (3%), and gout (3%). In subgroup analysis of RA patients, female preponderance was observed and the frequent biochemical investigations were erythrocyte sedimentation rate and rheumatoid factor. C-reactive protein, anti-cyclic citrullinated peptides, and vitamin D estimations were less frequent. The comorbid conditions were diabetes and hypothyroidism and concominant arthritis were connective tissue disorders, Sjogren's syndrome, and fibromyalgia. Medication profile revealed polypharmacy with disease modifying antirheumatics, glucocorticoids, analgesics and non-steroidal anti-inflammatory drugs. Conclusion: This study provides basic information of different types of arthritis and RA was found to be the most common. Female preponderance, polypharmacy, comorbid conditions and concominant arthritis may have implications for further research on the disease management.

show abstract

“…Although some clinical and serologic factors have been shown to be associated with response to certain treatment options 12, 13, there have yet been no consistent predictors that could identify an individual patient with a higher chance of responding to a particular therapy compared with another 14, 15.…”

mentioning

confidence: 99%

A Multi‐Biomarker Disease Activity Score and the Choice of Second‐Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure

Hambardzumyan

Saevarsdóttir

Forslind

et al. 2017

Arthritis & Rheumatology

View full text Add to dashboard Cite

ObjectiveTo investigate whether the Multi‐Biomarker Disease Activity (MBDA) score predicts optimal add‐on treatment in patients with early rheumatoid arthritis (RA) who were inadequate responders to MTX (MTX‐IRs).MethodsWe analyzed data from 157 MTX‐IRs (with a Disease Activity Score using the erythrocyte sedimentation rate [DAS28‐ESR] >3.2) from the Swedish Pharmacotherapy (SWEFOT) trial who were randomized to receive triple therapy (MTX plus sulfasalazine plus hydroxychloroquine) versus MTX plus infliximab. The MBDA score as a predictor of the subsequent DAS28‐based response to each second‐line treatment was analyzed at randomization with the Breslow‐Day test for 2 × 2 groups, using both validated categories (low [<30], moderate [30–44], and high [>44]) and dichotomized categories (lower [≤38] versus higher [>38]).ResultsAmong the 157 patients, 12% had a low MBDA score, 32% moderate, and 56% high. Of those with a low MBDA score, 88% responded to subsequent triple therapy, and 18% responded to MTX plus infliximab (P = 0.006); for those with a high MBDA score, the response rates were 35% and 58%, respectively (P = 0.040). When using 38 as a cutoff for the MBDA score (29% patients with lower scores versus 71% with higher scores), the differential associations with response to triple therapy versus MTX plus infliximab were 79% versus 44% and 36% versus 58%, respectively (P = 0.001). Clinical and inflammatory markers had poorer predictive capacity for response to triple therapy or MTX plus infliximab.ConclusionIn patients with RA who had an inadequate response to MTX, the MBDA score categories were differentially associated with response to subsequent therapies. Thus, patients with post‐MTX biochemical improvements (lower MBDA scores) were more likely to respond to triple therapy than to MTX plus infliximab. If confirmed, these results may help to improve treatment in RA.

show abstract

Clinical and Serological Predictors of Remission in Rheumatoid Arthritis Are Dependent on Treatment Regimen

Cited by 13 publications

References 29 publications

The Relationship Between Mental Health, Disease Severity, and Genetic Risk for Depression in Early Rheumatoid Arthritis

The Relationship Between Mental Health, Disease Severity, and Genetic Risk for Depression in Early Rheumatoid Arthritis

Epidemiology of Autoimmune Disorders with Special Reference to Rheumatoid Arthritis from a Tertiary Care Center

A Multi‐Biomarker Disease Activity Score and the Choice of Second‐Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure

Contact Info

Product

Resources

About